文献速递胃肠动力与功能性疾病

幽门扩张性测量可预测幽门内肉毒杆菌毒素注射的症状反应

Pyloric distensibility measurement predicts symptomatic response to intrapyloric botulinum toxin injection.
PubMed 文献 · Gastrointest Endosc · 2019-04-25

本研究评估幽门扩张性测量能否预测胃轻瘫患者幽门内肉毒杆菌毒素注射后的症状反应。35例患者中19例幽门扩张性异常(<10 mm2/mm Hg),该组注射3个月后总症状评分从13.5降至10.5(P<.01),生活质量指数从59.5升至76.5(P=.02),胃排空半衰期从223分钟降至190分钟(P=.02);而扩张性正常组各项均无显著变化。

要点

  • 幽门扩张性异常(<10 mm2/mm Hg)的胃轻瘫患者,注射后3个月总症状评分从13.5降至10.5(P<.01)。
  • 扩张性异常组胃胀满从3.5降至2.5(P=.03)、腹胀从3.0降至2.0(P=.01),扩张性正常组均无改善。
  • 扩张性异常组生活质量指数从59.5升至76.5(P=.02),胃排空半衰期从223分钟降至190分钟(P=.02)。

核心结论

  • 幽门内肉毒杆菌毒素注射前测量幽门扩张性可预测胃轻瘫患者注射3个月后的症状和生活质量反应。

研究设计与样本

  • 前瞻性研究,共纳入35例胃轻瘫患者,注射前用EndoFLIP系统测量幽门扩张性,注射前及注射3个月后评估总症状评分、消化不良症状、胃肠道生活质量指数和胃排空。

主要发现

  • 扩张性异常组总症状评分3个月时从13.5降至10.5(P<.01),扩张性正常组无变化(P=.7)。
  • 扩张性异常组胃胀满从3.5降至2.5(P=.03)、腹胀从3.0降至2.0(P=.01),扩张性正常组无任何症状改善。
  • 扩张性异常组胃肠道生活质量指数从59.5升至76.5(P=.02),扩张性正常组无统计学差异(P=.43)。
  • 扩张性异常组胃排空半衰期从223分钟降至190分钟(P=.02),扩张性正常组无变化(P=.6)。

关键数值与推荐

  • 幽门扩张性异常定义为扩张性低于10 mm2/mm Hg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Recent studies have reported that pyloric distensibility was altered in 30% to 50% of patients with gastroparesis, and this was correlated with gastric emptying and symptom severity. The aim of this study was to assess whether pyloric distensibility measurement was predictive of symptomatic response after intrapyloric botulinum toxin (BT) injection. METHODS: Pyloric distensibility was measured using the EndoFLIP system (Crospon, Galway, Ireland) before intrapyloric BT injection. Altered pyloric distensibility was defined as distensibility below 10 mm2/mm Hg. Total symptomatic score (TSS), dyspeptic symptoms, Gastrointestinal Quality of Life Index (GIQLI), and gastric emptying were investigated prospectively before and 3 months after BT injection. RESULTS: Nineteen of 35 patients had altered pyloric distensibility. In those patients, TSS decreased at 3 months from 13.5 to 10.5 (P < .01), whereas it remained unchanged in patients with normal pyloric distensibility (P = .7). Gastric fullness (from 3.5 to 2.5; P = .03) and bloating (from 3.0 to 2.0; P = .01) were the only symptoms that improved in patients with altered pyloric distensibility, whereas none of them was improved in patients with normal pyloric distensibility. GIQLI score increased from 59.5 to 76.5 in patients with altered pyloric distensibility (P = .02), whereas there was no statistical difference (P = .43) in patients with normal pyloric distensibility. In patients with altered pyloric distensibility, gastric emptying half time was 223 minutes before and 190 minutes 3 months after injection (P = .02), whereas it remained unchanged in patients with normal pyloric distensibility (P = .6). CONCLUSIONS: Pyloric distensibility measurement before intrapyloric BT injection predicted symptomatic and quality of life response 3 months after injection in patients with gastroparesis.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Desprez C, Melchior C, Wuestenberghs F, et al. Pyloric distensibility measurement predicts symptomatic response to intrapyloric botulinum toxin injection. Gastrointest Endosc. 2019. PMID: 31028783. doi:10.1016/j.gie.2019.04.228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。